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Abstract
Background: Pathogen genomics is increasingly being translated from the research setting into the activities of
public health professionals operating at different levels. This survey aims to appraise the literacy level and gather
the opinions of public health experts and allied professionals working in the field of infectious diseases in Belgium
concerning the implementation of next-generation sequencing (NGS) in public health practice.
Methods: In May 2019, Belgian public health and healthcare professionals were invited to complete an online
survey containing eight main topics including background questions, general attitude towards pathogen genomics
for public health practice and main concerns, genomic literacy, current and planned NGS activities, place of NGS in
diagnostic microbiology pathways, data sharing obstacles, end-user requirements, and key drivers for the
implementation of NGS. Descriptive statistics were used to report on the frequency distribution of multiple choice
responses whereas thematic analysis was used to analyze free text responses. A multivariable logistic regression
model was constructed to identify important predictors for a positive attitude towards the implementation of
pathogen genomics in public health practice.
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Results: 146 out of the 753 invited public health professionals completed the survey. 63% of respondents indicated
that public health agencies should be using genomics to understand and control infectious diseases. Having a high
level of expertise in the field of pathogen genomics was the strongest predictor of a positive attitude (OR = 4.04,
95% CI = 1.11 – 17.23). A significantly higher proportion of data providers indicated to have followed training in the
field of pathogen genomics compared to data end-users (p < 0.001). Overall, 79% of participants expressed interest
in receiving further training. Main concerns were related to the cost of sequencing technologies, data sharing, data
integration, interdisciplinary working, and bioinformatics expertise.
Conclusions: Belgian health professionals expressed favorable views about implementation of pathogen genomics
in their work activities related to infectious disease surveillance and control. They expressed the need for suitable
training initiatives to strengthen their competences in the field. Their perception of the utility and feasibility of
pathogen genomics for public health purposes will be a key driver for its further implementation.
Keywords: Public health practice, next-generation sequencing, pathogen genomics, whole-genome sequencing, survey
Introduction
Sequence information from viruses, bacteria, and other
infectious organisms can be used to identify a pathogen
and its specific characteristics, and compare its genetic
relatedness to other pathogens [1]. Advances in sequen-
cing technologies, especially the shift to next-generation
sequencing (NGS), have made it possible to analyze
pathogen genomes in much greater detail. Compared to
Sanger sequencing, NGS technologies allow a faster and
cheaper way to sequence larger lengths of nucleotides.
As such, NGS makes microbial pathogen whole-genome
sequencing (WGS) accessible in high throughput within
a matter of days [1]. During the last decade, NGS has ex-
panded beyond the research settings and is being rapidly
applied into routine practice for public health and food
safety [1–6].
In public health, integrating pathogen genomics with
epidemiology provides many opportunities for improving
the population-level risk assessment and management of
infectious diseases [1–8]. The main applications of WGS
include (1) retrospective (or near real-time) comparisons
of pathogens’ relatedness to test epidemiological trans-
mission hypotheses of suspected outbreaks (i.e. outbreak
investigations); (2) WGS-based prospective surveillance
by monitoring of cases generating alerts when clusters of
pathogens with similar genomes are identified in a lim-
ited geographical area or time period or when virulent
clones emerge (outbreak detection by control-oriented
surveillance); and (3) cross-sectional genomic epidemi-
ology surveys to monitor long-term changes in epidemi-
ology over larger geographic and population scales to
inform prevention strategies (strategy-oriented surveil-
lance) [9]. The main added value of implementing WGS
during surveillance activities or outbreak investigations is
inherent in the higher resolution of the WGS output itself,
leading to an increased sensitivity and specificity to iden-
tify transmission clusters compared to conventional sub-
typing methods [6]. As such, there are numerous success
stories of outbreak investigations applying WGS that were
able to identify to the source of infection and implement
targeted control measures to stop further spread, saving
resources at the health protection and local authority level
[10–17]. Other concrete examples of the utility of WGS
for national surveillance and local infection control in-
clude the guidance of vaccination strategies [18–21] and
antibiotic stewardship [22, 23]. Besides transforming the
public health approach to infectious diseases monitoring,
analysis of pathogen genomics can advance the accuracy
of infection diagnostics and guide the treatment of indi-
vidual patients [4, 24–29]. For several pathogens, NGS is
able to replace current time-consuming and/or labor-
intensive conventional methods with a single, all-in-one
diagnostic test [30–33].
Public health professionals play a key role in protect-
ing the population against communicable disease threats.
This requires them to give effective responses in a lim-
ited time frame, supported by adequate information
resulting from applying the most appropriate tools
adapted to the specific public health threat scenario. In-
fectious disease surveillance systems build upon the co-
operation between: clinicians, who are at the frontline
through identification of infected patients; microbiolo-
gists, who are involved in testing specimens; molecular
biologists, who study organisms at the molecular level;
bioinformaticians, who develop computational ap-
proaches/algorithms to analyze genomic data; epidemiol-
ogists, who use the data to understand patterns in
disease occurrence at the population level; infection
control practitioners, who are responsible for local pre-
vention and control of infectious diseases in the commu-
nity; hospital hygienists, who are involved in the
prevention and control of healthcare-associated infec-
tions; food safety inspectors, who monitor food prod-
ucts; etc. The activities of these public health experts
operating at different levels in the information cycle will
be impacted by the introduction of pathogen genomics
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as they are all connected to each other. This ranges from
microbiologists adapting their laboratory workflows to
epidemiologists rethinking their current data analysis
approaches.
Typically, new laboratory technologies are adopted by
data providers first, while data end-users might not be
familiar enough with the new methods to effectively
translate the output data into public health actions. Ex-
pertise with pathogen genomics and its applications for
public health practice might also differ between those in
charge of national surveillance of infectious diseases and
those involved in local infection control and patient
management, as well as between different fields (i.e. hu-
man, animal, food, and the environment) within the One
Health spectrum [34, 35].
Differences in perceptions and needs between these
different profiles should be taken into account before we
can build a strategy that engages all the stakeholders in
an effective collaboration. The key to success in translat-
ing pathogen genomics into public health practice is to
demonstrate an added value by better addressing the
needs and expectations of the whole range of public
health experts. An effective exchange of expertise across
disciplines (e.g., clinicians, microbiologists, epidemiolo-
gists, and bioinformaticians) is key for enabling the
smooth implementation of NGS into routine public
health activities. If such coordination of joint efforts can-
not be accomplished, the technology shift, which is cur-
rently ongoing, might not realize its full potential [5, 8].
Previous surveys in the field of public health genomics
focused on: human genomics [36–38]; specific aspects
such as proficiency testing [39], the design of WGS clin-
ical reports [39] or data sharing [40]; or specific target
groups such as National Microbiology Focal Points [41]
or food safety laboratories [42]. In this study, by organiz-
ing an online survey, we aimed to perform a wide land-
scape analysis of all potentially involved stakeholders in
order to appraise the level of genomic literacy and to
gather the opinions of public health experts and allied
professionals working in the field of infectious diseases
in Belgium concerning the implementation of NGS in
routine public health activities, in terms of its utility,
feasibility, implementation, and translation into action-
able results for public health decision making.
Methods
An electronic questionnaire survey (see Additional file 1)
was developed for this study using LimeSurvey (Version
2.71.1) [43] for the collection of relevant information from
public health professionals working in the field of infec-
tious diseases in Belgium. For the purposes of this study, a
‘public health professional in the field of infectious dis-
eases’ was defined as a person with professional expertise
in the field of infectious diseases and who directly or
indirectly contributes to the population-level management
of infectious diseases. To provide a complete picture of all
involved stakeholders, the survey aimed to reach different
subgroups based on professional qualification (i.e. micro-
biologists, molecular biologists, bioinformaticians, epide-
miologists, clinicians, clinical biologists, infection control
practitioners, and hospital hygienists), employing institu-
tion (i.e. governmental, private, hospital, and university),
health field (i.e. human, animal, food, and environment),
expertise in pathogens (i.e. bacteria, viruses, parasites,
fungi, and yeasts), and level of action (i.e. national surveil-
lance and local infection control). To identify all actors in
the field of public health activities for infectious diseases,
an overview was made of existing surveillance systems (i.e.
data sources) in Belgium (see Additional file 2). The set of
questions was compiled based on the literature, including
several review articles [1–3, 5, 7, 24–26, 44, 45]. Existing
items from previous survey questionnaires [27, 36–42,
46]) were used and adapted when relevant. Most of the
existing questionnaires from which some questions were
adapted to be used for this survey were not validated, ex-
cept for Chow-White et al. 2017 as mentioned in the re-
spective publication [37]. The construction of the survey
was discussed during several feedback rounds within a
multidisciplinary team including epidemiologists, microbi-
ologists, and molecular biologists. As a result, the survey
instrument was vetted by subject matter experts. The
questionnaire eventually contained eight main topics com-
prising background questions, general attitude towards
pathogen genomics for public health practice and main
concerns, genomic literacy, current and planned NGS ac-
tivities, place of NGS in the diagnostic hierarchy of micro-
biology, data sharing obstacles, end-user requirements,
and key drivers for the implementation of NGS. Based on
a filter question where participants indicated their level of
familiarity with pathogen genomics, the respondents were
redirected to different sets of questions with different
levels of technicity and detail. The filter question gave ac-
cess to a reduced version of the questionnaire for those
participants judging themselves as not at all familiar with
pathogen genomics. The responses were mainly collected
as single/multiple options from a set of pre-defined an-
swers, but also included the optional entry of free text.
These qualitative open questions were included to add
context to the quantitative responses. The survey tool was
pre-tested by three researchers not directly involved in the
development phase to ensure the acceptability and clarity
of the questionnaire.
Participants were contacted individually by an email
invitation containing a personal token to complete the
survey. No monetary or other incentive was offered. The
participant information statement at the beginning of
the survey informed the respondents about the objective
and design of the study and their rights before
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participation to the survey, and explained that responses
are anonymized and will be kept confidential. The ap-
proval from an Ethical Committee was not considered
necessary due to national regulations (legislation 4 April
2014), as this study was not medical in nature and as
participants were not subject to any actions and/or rules
of conduct. The survey was available online during a two
months’ period during which three reminders were sent
to those who had not yet responded. The first invitations
were sent on the 6th of May 2019 and the survey
remained active until the 1st of July 2019. Participants
were invited to send any questions, feedback or com-
ments for the survey to the organizers. Only completed
questionnaires were used for analysis.
Descriptive statistics were reported by analyzing cat-
egorical response frequencies. Differences in viewpoints
between the stakeholders were described using subgroup
analyses and compared using a Fisher’s exact test. Sub-
groups were compiled on the basis of the level of action
(national vs. local), the position in the information cycle
(data providers vs. data end-users), and the level of ex-
pertise in the field of pathogen genomics. The level of
action was considered national when the main affiliation
of the respondent concerned a national institute in-
volved in national public health activities, whereas the
local level included professionals who mainly operate at
the community, hospital, or university level. Subgroups
based on the position in the information cycle were de-
fined as data providers, defined here as experts in wet
and dry lab procedures and (potentially) generating NGS
data (including microbiologists, molecular biologists,
clinical biologists, and bioinformaticians), and data end-
users defined here as using NGS data to improve their
activities and implementing infection control measures
(including epidemiologists, local infection control practi-
tioners, hospital hygienists, and clinicians). The level of
expertise was categorized as high, middle or low, and
was based on respondents’ self-reported familiarity with
pathogen genomics, training level, and current use of
NGS. Multiple logistic regression was performed to
identify predictors of a positive attitude towards the im-
plementation of pathogen genomics from a public health
perspective. Enthusiasm about public health agencies
using genomics to understand and control infectious dis-
eases was defined directly through a question with mul-
tiple options, each containing a clear statement (see
Additional file 1). For the purpose of this analysis, the
question asking about their enthusiasm originally con-
sisting of multiple categories was collapsed into two
levels: very enthusiastic versus all others. The following
predictor variables were initially tested in the model:
level of action; position in the information cycle; level of
expertise; current use of NGS; institution; age group;
years of professional experience; and position in their
institution. Model building involved a univariate analysis
to select variables to be included in the multivariable
model based on a χ2-test (cut-off, P = 0.25), and variable
selection from the multivariable model using backward
stepwise regression based on the Akaike Information
Criterion (AIC). Adjusted odds ratios (ORs) and 95%
confidence intervals (CIs) were calculated. Quantitative
analyses were performed using R software (R Studio ver-
sion 1.0.153) [47]. Answers to open-ended survey ques-
tions were summarized and analyzed using Nvivo
qualitative data analysis software (Nvivo Version 12)
[48]. This was done by identifying themes (codes) within
the data, which were derived both deductively and in-
ductively. Following the thematic analysis framework,
the text was compared and contrasted with the identified
codes. The qualitative findings were summarized as a
mind map linking the identified major and minor
themes and a word cloud visualizing the word frequency
from the qualitative responses. Simultaneously, quotes
were selected for the sake of illustration.
Results
Profile of the respondents
Out of the 753 invited participants, 465 did not respond
at all, 142 partially filled in the survey, and a total of 146
participants delivered a completed survey which repre-
sents an overall survey response rate of 19% (Fig. 1).
From these, 135 participants continued after the filter
question and delivered answers to all questions (116
subject were redirected to a technical version of the sur-
vey and 19 subjects to a basic version, based on the filter
question). The data from the 11 participants who pre-
ferred to quit after the filter question were only used to
describe the background characteristics of the study
population. The 142 subjects who partially filled in the
survey were dropped completely from the analysis. Full
responses to all questions as they appeared in the ques-
tionnaire are provided as an appendix to this report (see
Additional file 3).
Background characteristics of the 146 participants are
presented in Table 1. The majority of respondents had
their main affiliation in the public sector (53%), followed
by hospitals (including university hospitals) (36%), pri-
vate sector (8%), and university (3%). The public sector
was primarily represented by Sciensano (Belgian Insti-
tute for Health), comprising 42% of all survey partici-
pants (61/146). 53% of the respondents indicated that
they had more than 10 years of professional experience
within the field of infectious diseases. The reported roles
of respondents within their institutions included: micro-
biologists/molecular biologists/bioinformaticians/clinical
biologists (45%); epidemiologists (21%); clinicians (13%);
hospital hygienists/infection control practitioners (10%);
and policy makers (3%).
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The 146 survey respondents were asked to describe
their level of familiarity with sequencing technologies
and pathogen genomics using following classification:
‘Very - I am involved in the generation and/or use of
NGS data’ (22%), ‘Somewhat - I have a general sense of
the applications of NGS’ (58%), or ‘Not at all - I don't
know anything about NGS and its applications’ (21%).
Of those participants answering ‘very familiar’, most of
them (88%; 28/32) indicated that they mainly used NGS
in the context of WGS. Of those ‘not at all familiar’, 11
preferred to quit the survey and 19 continued the survey
to answer some general questions, leaving a total of 135
participants for the remainder of the survey (Fig. 1).
Subgroup analysis showed differences in familiarity with
pathogen genomics between data providers and end-
users (Fig. 2). Data providers indicated significantly more
frequently that they were ‘very familiar’ compared to
data end-users (p < 0.001).
Attitude
The majority of respondents (63%; 85/135) indicated
that they were very enthusiastic (i.e. ‘we should be using
genomics now’) about public health agencies using gen-
omics to understand and control infectious diseases,
30% (40/135) did not have an opinion or did not know
enough of the topic to be able to give an opinion, and
7% (10/135) indicated that they did not see clear applica-
tions and/or an added value for public health. Subgroup
analysis pointed out differences in enthusiasm according
to the level of expertise in the field of pathogen genom-
ics (Fig. 3). Important predictors, as identified by the
best fitting model, of a positive attitude related to the
implementation of pathogen genomics from a public
health perspective were the level of expertise, the level of
action, and the position in the information cycle
(Table 2). Participants classified as having a high level of
expertise based on their self-reported familiarity with the
topic, their training level, and/or the current use of NGS
were significantly more likely to be enthusiastic about
the implementation of pathogen genomics in a public
health context compared to their peers with a low ex-
pertise (adjusted OR = 4.04, 95% CI = 1.11 – 17.23).
Further, public health professionals operating at the na-
tional level were more often ‘very enthusiastic’ about the
implementation of pathogen genomics (71%) compared
to those at the local level (53%). Similarly, data providers
were more often ‘very enthusiastic’ (76%) compared to
data end-users (50%).
Fig. 1 Flow chart of the participants in the survey, Belgium, 2019
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Expected impact
A large majority of respondents considered the following
public health activities as likely to be most impacted by
pathogen genomics in the next five years: identifying an
outbreak (clusters of related isolates) (78%; 105/135),
nosocomial and food/waterborne outbreak investigations
(76%; 103/135), and monitoring the spread of antimicro-
bial resistance (71%; 96/135). In contrast, only 44% (60/
135) of respondents thought that pathogen genomics
would have a major impact on making a diagnosis and
selecting an appropriate treatment (individual patient
management). Other public health activities that will
benefit from the implementation of pathogen genomics
mentioned by the participants are presented in Table 3.
Concerns
The most frequent concerns among participants being
‘very’ or ‘somewhat’ familiar with NGS technologies and
pathogen genomics (n=116) regarding feasibility of its rou-
tine use for public health purposes, were the cost of se-
quencing technologies and the existing barriers to timely
and open sharing of pathogen sequence data and accom-
panying metadata (Table 4). All participants exclusively
working with respiratory infections (e.g. influenza) and/or
vaccine-preventable diseases (e.g. measles) (n=7) were very
concerned about the cost, whereas this was only true for
38% of participants exclusively working with invasive bac-
terial diseases (e.g. Neisseria meningitidis), food- and
waterborne diseases (e.g. Salmonella), and/or healthcare-
associated infections (e.g. Clostridium difficile) (n=21).
Further, other concerns shared by a large proportion of
Table 1 Demographic characteristics of the 146 public health
professionals working in the field of infectious diseases who
completed the survey ‘Perceived utility and feasibility of
pathogen genomics for public health practice’, Belgium, 2019
Variables Frequency Percentage
Primary employer
Public sector 77 53%
Private sector 12 8%





National Reference Center 19 68%
Sentinel/peripheral laboratory 7 25%
Other 2 7%
Molecular biologist 16 11%
Bioinformatician 5 3%
Clinical biologist 17 12%
Clinician 19 13%
Hospital hygienist 7 5%
Infection control practitioner 7 5%









Years of professional experience in the field of infectious diseases







Lower management 43 29%
Middle management 36 25%
Upper management 15 10%
Other 8 5%




Table 1 Demographic characteristics of the 146 public health
professionals working in the field of infectious diseases who
completed the survey ‘Perceived utility and feasibility of




Infectious diseases group(s) (multi-group designation was allowed)










Body-fluid related infectious diseases






(e.g. Clostridium difficile, MRSA)
72 49%
Animal diseases 20 14%
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the participants were interdisciplinary cooperation, inte-
gration of pathogen sequence data with contextual data,
access to bioinformatics expertise, and availability of typ-
ing schemes and databases. Participants indicating to be
‘not at all’ familiar with pathogen genomics were mainly
concerned about the cost of the sequencing technologies
(see full responses in Additional file 3). Other concerns
provided by the participants as free text are presented in
Table 3.
Genomic literacy
Two-thirds of the participants (88/135) indicated that they
had followed training in the fields of genomics/genetics/
molecular biology/bioinformatics. There were marked
Fig. 2 Familiarity of participants with pathogen genomics according to their position in the information cycle, Belgium, 2019. Subgroups: (i) data
providers (n=69) including microbiologists, molecular biologists, bioinformaticians, and clinical biologists, and (ii) data end-users (n=77) including
epidemiologists, local infection control practitioners, hospital hygienists, and clinicians. Categories: (i) ‘Very - I am involved in the generation and/or use of
NGS data’, (ii) ‘Somewhat - I have a general sense of the applications of NGS’, and (iii) ‘Not at all - I don't know anything about NGS and its applications’
Fig. 3 Enthusiasm of participants regarding the use of pathogen genomics for public health practice according to level of expertise in the field of
pathogen genomics, Belgium, 2019. Subgroups: (i) High (n=32) (indicated ‘Very familiar’ and currently generating or using NGS data or continuing
education in the field of genomics or professional experience in the field of genomics), (ii) Middle (n=51) (indicated ‘Somewhat familiar’ and having
followed training in the field of genomics), and (iii) Low (n=52) (indicated ‘Not at all familiar’ or indicated ‘Somewhat familiar’ and having never
followed training in the field of genomics). Categories: (i) ‘Very enthusiastic – we should be using genomics now’, (ii) ‘Neutral – I do not have an
opinion on genomics in public health’, (iii) ‘Skeptical – genomics may be useful for research purposes, but I do not see clear applications and/or an
added value for public health’, (iv) ‘It’s all a hype – genomics has not proven itself to be more useful than the conventional methods, we should not
invest resources/time in genomics’, and (v) ‘I don’t know – I don’t know enough of the topic to be able to give an opinion’
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differences by position in the information cycle: 56% (38/
68) of data end-users indicated that they had never
followed any training in the field, whereas this was stated
by only 13% (9/67) of data providers (p < 0.001). Further
breakdown of training experience by professional category
is shown in Fig. 4.
The main reasons for not taking a training/course in
this field (yet) were the lack of available and/or suitable
trainings (40%; 19/47) and the lack of time (30%; 14/47).
Other reasons indicated as free text are presented in
Table 3. The vast majority of participants (79%, 106/135)
indicated that they felt the need and/or would be inter-
ested in following (additional) courses/training/work-
shops covering a topic related to pathogen genomics.
Current and planned NGS activities
Overall, 36% (42/116) participants being ‘very’ or ‘some-
what’ familiar with NGS technologies and pathogen gen-
omics indicated that they are currently using or
generating NGS data for at least one pathogen. Differ-
ences between professional groups are presented in
Fig. 5. Among the microbiologists, those from a National
Reference Centre (NRC) were more likely to be currently
using NGS (12/18, i.e. 67%) compared to those from
other laboratories (1/7, i.e. 14%), however this difference
was not significant (p=0.71). From the public health pro-
fessionals exclusively involved in human infectious dis-
ease activities, 30% (21/70) were currently using NGS
technologies, whereas this was the case for 44% (11/25)
of those exclusively involved in the food, animal or en-
vironmental sector (p=0.23).
Looking forward, 44% (51/116) of participants indi-
cated that they were planning to use or generate NGS
data for any (additional) pathogen(s) within three years.
Details on the specified pathogens can be found in the
appendix (see Additional file 3). Reasons provided by
participants indicating that they did not plan to imple-
ment pathogen genomics were mainly related to the cost
and the lack of expertise.
Key drivers for implementation
Participants being ‘very’ or ‘somewhat’ familiar with
NGS technologies and pathogen genomics (n=116) were
asked to assign a score from 1 to 5 to the different cri-
teria based on their increasing relative importance to de-
cide whether or not NGS should be implemented for a
particular pathogen (Fig. 6). Clinical and/or public health
significance of the pathogen were scored as the most
important drivers. The different subgroups scored the
different criteria similarly (see Additional file 3). Com-
ments provided by the participants to provide context to
their scores are presented in Table 3.
Laboratory workflow integration
Centralization of sequencing and bioinformatics at NRCs
organized per pathogen or per group of pathogens was
most often (34%; 40/116) selected by respondents being
‘very’ or ‘somewhat’ familiar with pathogen genomics as
the preferred WGS provision model in the Belgian con-
text. Excluding participants working at NRCs slightly
lowered this proportion to 29 out of 98 (i.e., 30%). There
were no marked differences according to the level of ac-
tion of the participants (Fig. 7). Illustrative quotes for
the need for centralization are presented in Table 3.
Table 2 Determinants of public health professionals’ positive attitude towards the implementation of pathogen genomics in a
public health context, Belgium, 2019
Variablesa Total Very enthusiasticb Crude Adjustedc
N n (%) OR (95% CI) OR (95% CI)
Level of expertise
Low (reference) 52 25 (48.1) 1.00 1.00
Middle 51 32 (62.7) 1.82 (0.83 – 4.04) 1.54 (0.68 – 3.52)
High 32 28 (87.5) 7.56 (2.53 – 28.27) 4.04 (1.11 – 17.23)
Level of action
Local (reference) 57 30 (52.6) 1.00 1.00
National 78 55 (70.5) 2.15 (1.06 – 4.42) 2.07 (0.96 – 4.52)
Position in information cycle
Data end-user (reference) 68 34 (50.0) 1.00 1.00
Data provider 67 51 (76.1) 3.19 (1.55 – 6.78) 2.09 (0.88 – 5.09)
OR odds ratio, CI confidence interval
aVariables were selected using backward stepwise regression based on the Akaike Information Criterion from a multivariable logistic model
bParticipants were classified as those who were ‘very enthusiastic – we should be using genomics now’ concerning the implementation of pathogen genomics in
public health practice vs. all others
cOdds ratios adjusted for the set of variables included in the final multivariable logistic regression model (i.e. level of expertise, level of action, and position in
information cycle)
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Table 3 Illustrative quotes selected from the qualitative survey data, Belgium, 2019
Topic Subtopic Illustrative quotes
Public health activities, other than those
provided within the survey, that will benefit
from the implementation of pathogen
genomics
Environmental monitoring “drinking water quality”
“air quality, home environmental quality”
Metagenomics “metagenomics for patients with no identified cause of illness
using conventional methods”
“identification and characterization of new strains”
“insights in dysbiosis”
“microbiome analysis”
Other “discovery of a causal relation between a pathogen and a
clinical disease (e.g. cancer)”
“vaccine development”
“phage therapy”
“early diagnostics of diseases due to slow growing pathogens”
“international tracking”
“monitoring of antiviral resistance”
Concerns, other than those provided within
the survey, related to the implementation of
pathogen genomics for public health practice
Contextual data “harmonization of epidemiological data – most of the
epidemiological data is very ‘messy’ or inconsistent, which
makes systematic integration and surveillance unfeasible”
“data collection is already limited so newer technologies will not
automatically improve this process but be redundant if the
basics are not met”
Interpretation and
education
“how to interpret the result at clinical level”
“[…] they need to have a basic understanding (education) it
order to understand and see cost/benefit of the whole picture”




Ethics “[…] healthcare workers integrity concerns”
“in the HIV field, the phylogenetic analyses of virus permit to
have an hindsight in paths of transmission – it is a very tricky
topic in ethical and potentially legal aspects”
Other “does the identification prove that the pathogen poses a risk?”
“the fear that some actors in the field will try to abuse their
power and monopolize this new technology – to be really
valuable to patient management and public health it is required
to offer access to all laboratories”
“high inter-laboratory variability”
“[…] standardization and facilities for data sharing need to be
improved”
“the perceived utility and feasibility of pathogen genomics by
public health practitioners is the biggest bottleneck of all – all
the other concerns listed above can be tackled given the drive
within the field to solve them in the first place”
Reasons, other than those provided within the
survey, for not taking a training/course in the
field of pathogen genomics
“lack of training adapted to public health needs”
“not applicable for a clinician”
“not my priority”
“not relevant for my practice”
Key drivers for implementation of pathogen
genomics
“depends on the evolution in phenotypic typing”
“[…] the main driver the pressure by ECDC rather than a real
need for public health […] the first and main driver should be
clinical significance: improve quality of care for the patient”
“for bacteria, NGS will never fully replace classical methods for
resistance testing, but would offer important complementary
data”
“cost-effectiveness (e.g. replacing multiple tests): not particularly
true for viruses, but obvious for bacteria”
Laboratory workflow integration Centralization “[…] should be overall coordinated and controlled by the federal
public health authority”
“[…] in any scenario it will be important that sequence data are
brought together in one databank for surveillance purposes”
Data sharing Organizational aspects “no central BE or EU organization”
“no central database, no clear guidelines on how and what to
share”
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Data sharing
A majority (59%; 68/116) of the participants being ‘very’
or ‘somewhat’ familiar with pathogen genomics consid-
ered technical barriers (lack of data standardization,
poor data quality, missing metadata, etc.) as a major obs-
tacle for sharing pathogen sequence data and associated
metadata, whereas only 38% (44/116) cited ethical issues
and concerns, 35% (41/116) political sensitivities, and
27% (31/116) priority to scientific publication. The pro-
portion of participants indicating priority to scientific
publication as a major obstacle for data sharing did not
significantly differ between those primarily affiliated to a
university (including university hospitals) compared to
the other participants. Concerns about organizational as-
pects are presented in Table 3.
Qualitative analysis results
Major themes identified within the qualitative data are util-
ity (applications), feasibility (including capacity building,
multi-disciplinary working, contextual data, costs, data
sharing, ethics, timeliness, wet and dry lab), One Health
context, and routine implementation (including organization
and translation into action). A mind map linking the identi-
fied major and minor themes is presented in Fig. 8. A full list
of identified themes and the coded text is available in
the appendix (see Additional file 4), as well as a word
cloud constructed based on the free text responses
(see Additional file 5).
Discussion
This survey sought the opinion of Belgian public health
professionals working in the field of infectious diseases
concerning the implementation of pathogen genomics in
public health activities. To successfully translate patho-
gen genomics into public health practice, the needs and
expectations of the different stakeholders should be
taken into account. Other questionnaire surveys related
to knowledge and attitudes towards public health
Table 3 Illustrative quotes selected from the qualitative survey data, Belgium, 2019 (Continued)
Topic Subtopic Illustrative quotes
“the bureaucracy involved in the transmission of data”
“the structure of public health in Belgium will not help sharing
data”
“the required technical infrastructure”
Priority to publication “it is really a pity that priority to publication is an obstacle in the
scientific world as it functions now”
One Health “A better collaboration between the veterinary and human side
might increase the use of NGS on the veterinary side”
“Monitoring the emergence and spread of zoonotic pathogens
has been impacted negatively, by the introduction of WGS at
the human side only”
Table 4 Concerns among participants being ‘very’ or ‘somewhat’ familiar with pathogen genomics expressed as the percentage
being ‘very’ or ‘somewhat’ concerned, Belgium, 2019. Subgroups: (i) data providers (n=62) including microbiologists, molecular
biologists, bioinformaticians, and clinical biologists, and (ii) data end-users (n=54) including epidemiologists, local infection control







Quality of the pathogen sequence data (validation and accreditation of both wet and dry lab protocols) 63% 73% 52%
Timeliness of the pathogen sequence data (turn-around time) 67% 76% 57%
Integration of pathogen sequence data with other types of data (e.g. clinical and epidemiological data) 70% 61% 79%
Linking pathogen sequence data from different sources (human/food/animal/environment) 59% 55% 64%
Translation of pathogen sequence data into public health action (usefulness) 68% 64% 71%
Interdisciplinary working/coordination between epidemiologists, microbiologists, bioinformaticians, etc. 75% 79% 70%
Cost of sequencing technologies 86% 87% 85%
Expertise and availability of personnel to be able to generate pathogen sequence data (wet lab) 60% 64% 55%
Expertise and availability of personnel to be able to analyze pathogen sequence data (bioinformatics) 75% 82% 67%
Timely and open sharing of pathogen sequence data and accompanying metadata 81% 89% 72%
Infrastructure (sequencers, high-performance computing, data storage, etc.) 67% 74% 59%
Availability of WGS typing schemes and reference databases (e.g. for antimicrobial resistance) 73% 79% 67%
Ethical and legal issues (e.g. patient privacy) 54% 56% 52%
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genomics in specific health expert categories have been
published [27, 36–39, 41, 42, 46, 49]. However, to the
best of our knowledge this survey is the first that aimed
to perform a wide landscape analysis of all potentially in-
volved stakeholders. Therefore, a strength of the current
study is that it took into account a wide range of stake-
holders with diverse backgrounds (epidemiologists,
microbiologists, bioinformaticians, clinicians, infection
control practitioners, etc.), health domains (human, food,
environmental, etc.), pathogen expertise (bacteria, vi-
ruses, parasites, fungi, etc.), activity sectors (public, pri-
vate, university, hospital, etc.), work positions (employee
and lower/middle/high management), and degree of fa-
miliarity with genomics. Besides seeking the general
attitude of the participants towards the implementation
of pathogen genomics in their professional activities and
investigating the current and future use, this explorative
study was able to touch upon multiple key topics, such
as genomic literacy, data sharing obstacles, place of NGS
in the diagnostic hierarchy of microbiology, and end-
user requirements.
Familiarity with sequencing technologies and pathogen
genomics varied between the different professional
groups, with data providers being more familiar than
data end-users. As shown before, one of the largest bar-
riers to acceptability from the public health unit is the
capacity to understand and use the data [50]. Possibly,
there is a positive association between genomic literacy
Fig. 4 Percentage of respondents who had received training in pathogen genomics by professional category, Belgium, 2019
Fig. 5 Percentage of NGS current users by professional category, Belgium, 2019
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Fig. 6 Boxplots of the scores of different key drivers for implementation of pathogen genomics rated by 116 participants, Belgium, 2019. Criteria
could be assigned a score from 1 to 5, or participants could indicate the ‘I don’t know’ option. The boxplots show the median score and the
interquartile range (grey boxes). The following criteria were included (top to bottom): clinical and/or public health significance, priority with
respect to preventing the spread of antimicrobial resistance, local/national/international policy surveillance priorities or obligations, importance of
prevention and control programs (e.g. vaccination), utility of WGS for diagnostics and/or treatment decisions (individual patient care), utility of
increased resolution to infer relatedness that would not be obtained via conventional methods, availability of high-quality/complete/standardized
epidemiological and/or clinical data to provide context to the WGS results, possibility to link genomic data from different sources (food-animal-
human-environment), cost-effectiveness (e.g. replacing multiple tests), time-saving compared to conventional testing methods, impact on
outcomes for patients and populations (translation into actionable results), availability of WGS typing schemes and reference databases (e.g. for
antimicrobial resistance), availability of validated (quality-controlled) WGS workflows (both wet and dry laboratory), availability of expertise to
generate, analyze and interpret WGS data, and availability of the appropriate infrastructure (sequence technology, high-performance computing,
data storage, etc.).
Fig. 7 Percentage of participants (n=116) selecting a particular WGS provision model by level of action, Belgium, 2019. 1 = Centralization of
sequencing and bioinformatics at one central sequencing center, 2 = Centralization of sequencing and bioinformatics at National Reference
Centers (which are organized per pathogen or group of pathogens), 3 = Decentralized point-of-care sequencing (at frontline laboratories), but
centralization of bioinformatics (mixed model), 4 = Decentralization of sequencing and bioinformatics, but mandatory submission of isolates to a
national repository, 5 = Decentralization of sequencing and bioinformatics, but mandatory submission of raw sequence data to a national
repository, 6 = Decentralization of sequencing and bioinformatics, but mandatory submission of bioinformatics output to a national repository
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and (critically) predicting the added value in public
health. Having a high level of expertise, was the stron-
gest predictor for a positive attitude, as was also shown
in other surveys [51–53]. Epidemiologists and infection
control practitioners should be informed about the ben-
efits and limitations of NGS technologies in order to
contribute in identifying tangible field application in
public health, allowing the use of WGS output to appro-
priately guide public health actions [38, 51]. Another im-
portant challenge related to the interpretation of WGS
data is the capacity to interpret signals, and thereby sep-
arating noise from public health events that require spe-
cific actions. Consequently, integrating genomics into
infection control and surveillance is critically linked to
human resource development [8, 24]. In the survey, the
main reasons stated for not training in the field of gen-
omics were lack of time or access to suitable trainings
“…adapted to public health needs”. However, the partici-
pants of this survey generally expressed a positive atti-
tude towards following (additional) training courses, or
workshops in pathogen genomics. Educational work-
shops should be applied to a public health context and
bring together the expertise of microbiologists, molecu-
lar experts, bioinformaticians, epidemiologists, infection
control practitioners, and clinicians. The development of
a new discipline called ‘genomic epidemiology’ integrat-
ing information on epidemiological and pathogen se-
quence characteristics by public health microbiologists,
epidemiologists, and risk managers was recommended in
the expert opinion on WGS for public health surveil-
lance by the European Centre for Disease Prevention
and Control (ECDC) in 2016 [8]. ECDC has initiated
public health genomics training workshops that bring to-
gether experts with epidemiology, microbiology and
pathogen genomics backgrounds from European Union
(EU) member states with interest in implementing the
technology in surveillance and outbreak investigations.
Besides, the zoonotic origin of many clinically relevant
pathogens and antimicrobial resistance determinants
stresses the importance of a cross-sectoral One Health
approach. The implementation of WGS should be syn-
chronized and integrated between the human health and
veterinary sectors [9] allowing a better monitoring of the
emergence and spread of zoonotic pathogens and anti-
microbial resistance-related threats.
Lack of financial resources was often indicated as a
principal reason for not using or planning to use WGS
by the respondents of this survey, which was also re-
ported by the European surveys conducted by ECDC
[41] and the European Food Safety Authority (EFSA)
Fig. 8 Mind map linking the major and minor themes identified in the qualitative responses, Belgium, 2019. Codes were identified within the
data deductively (i.e. themes that are expected and have been chosen in advance) and inductively (i.e. themes that are derived through analysis).
During the thematic analysis the qualitative data from the survey was compared and contrasted with the identified codes. As such, the derived
codes were assigned to the relevant text. Next, the codes (plain boxes) were merged into categories (colored boxes). The following categories
were identified: routine implementation (orange), One-Health context (yellow), and feasibility (blue)
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[42]. Operational costs will be influenced by the processes
used in current laboratory practice and differs between vi-
ruses and bacteria. Whereas drug susceptibility testing
and epidemiological typing are commonly performed for
bacteria, this is often not the case for viruses detected in
the routine laboratory [54]. Therefore, cost-effectiveness
of NGS for many bacteria potentially follows from the re-
placement of conventional characterization methods,
whereas for viruses NGS is considered as a tool providing
additional complementary information without replace-
ment of the existing methods. Further, an important con-
sideration is the added value of NGS for routine
diagnostics. As long as NGS is more expensive than the
conventional methods and when there is no direct benefit
for the individual patient, it will not be used in routine.
Then the fields of application for surveillance purposes
should be clearly defined to be able to justify the add-
itional financial resources needed to perform WGS beside
the diagnostic activities.
To translate pathogen sequence data into truly useful
and actionable information, it needs to be integrated
with other types of information (i.e. clinical and epi-
demiological data). In Belgium, most data end-users
were concerned about the challenges encountered with
the integration of pathogen sequence data with clinical
and epidemiological data. Indeed, the public health us-
ability of any kind of lab results, including WGS data, is
highly dependent on the cross-linkage with contextual
epidemiological and clinical information [8, 55, 56]. Data
integration is often hampered by the incomplete and/or
unstandardized nature of the contextual data [57]. The
ongoing digitalization of health data such as laboratory
and clinical records may represent an opportunity to re-
view and upgrade traditional data collection processes
for communicable disease surveillance.
According to World Health Organization’s (WHO)
2016 guidance on managing ethical issues in outbreaks
[58], rapid data sharing is crucial during an unfolding
health emergency. This suggests that pathogen sequence
data should be rapidly and openly shared at the start of
an outbreak, in many cases before scientific publication.
However, many barriers for data sharing remain including
authorship/attribution for publications, results dissemin-
ation, ethical considerations, data ownership, database ac-
cess agreements, etc. [59]. In our survey, practical barriers
(lack of data standardization, poor data quality, missing
metadata, etc.) seemed to be the major obstacles in
Belgium for sharing pathogen sequence data and associ-
ated metadata for public health purposes. Participants
mainly mentioned the lack of a central database and clear
guidelines. This reflects a lack of information on the ef-
fective data sharing through EU-wide genomic surveil-
lance and cross-border outbreak analysis systems
managed by ECDC and EFSA in support of the member
states [9, 60, 61]. Finally, 27% of participants considered
the priority to publication as a major bottleneck for shar-
ing pathogen sequence data. Publication priority is linked
to the importance of guaranteeing reputational returns to
research efforts [40, 62]. The challenge here is to find a
balanced arrangement that allows data sharing in real time
and the acknowledgement of research work by giving to
researchers who have been involved in data generation the
possibility to use and publish their own results in priority.
As the use of NGS shifts from research to routine labora-
tory practices, this data sharing barrier will slowly be
alleviated.
Regarding expertise and availability of personnel, wet
and dry lab experts were more concerned about the ana-
lysis of pathogen sequence data than the sequencing it-
self. As was mentioned in a review article of Aarestrup
et al. and documented in a recent European survey by
Revez et al., the most important limiting factor in many
countries is the lack of access to bioinformatics expert-
ise, especially when used as part of frontline diagnostics
[44] or national public health reference laboratory ser-
vice [41].
Another point of discussion is the potential impact of
NGS on the diagnostic microbiology pathway. Tradition-
ally, frontline clinical laboratories perform standard
identification, antimicrobial susceptible testing and occa-
sionally typing. Isolates may then be referred to refer-
ence laboratories based on the need (e.g. diagnostic
confirmation) or for surveillance purposes. These refer-
ence laboratories perform confirmation testing and ad-
vanced characterization. NGS was first implemented at
the level of academic or reference laboratories, because
of the need for investments, operational costs, and re-
quirements for expertise [24] while having limited added
value for individual patient care. Samples must be multi-
plexed (batching) for cost-effectiveness, which is easier
to achieve in large reference laboratories with high vol-
ume of sample throughput [26, 45]. However, processing
delays may be present when samples are shipped to a
reference center. These processing delays may result in
longer turnaround times rendering this centralized ap-
proach inappropriate to support a fast response when
needed. The reduced costs of sequencing facilitated the
introduction of NGS technology to frontline clinical la-
boratories. This shift towards a decentralized use may
reduce turnaround times, empower hospital-based
microbiology, and strengthen local infection control ef-
forts [24]. This decentralized capacity will allow the in-
clusion of these data in the surveillance network
coordinated by the epidemiologists what will compen-
sate the reduced referral of isolates to reference centers.
Consequently, the implementation of NGS in routine
labs is an important driver to reconsider the future role
of NRCs. Molecular typing for public health surveillance
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is undergoing a stepwise transition to NGS [41]. Current
and future NGS activities represented in this national
survey were mainly in the context of food- and water-
borne outbreak detections and investigations, reflecting
the priority for these diseases across Europe and beyond
[63, 64]. Several criteria should be considered in the
process of integrating WGS in a routine laboratory set-
ting [11] in order to know in which situations and for
which pathogens it is worthwhile to use NGS. Identify-
ing a set of key drivers that cover all aspects related to
the implementation of NGS (utility and feasibility) can
help to guide prioritization of pathogens and to effi-
ciently allocate resources. Clinical and/or public health
significance of the pathogen was scored as the most im-
portant driver during the implementation of pathogen
genomics in routine public health activities, followed by
availability of expertise to generate, analyze and interpret
WGS data, and priority of the pathogen with respect to
preventing the spread of antimicrobial resistance.
Qualitative responses revealed the opinion of several
participants that the assessment of the added value of
new technologies for individual patient care is para-
mount. If pathogen genomics is routinely used to guide
patient management (diagnosis and/or treatment op-
tions), the pathogen sequence data gathered for diagnos-
tic purposes can be accumulated for public health
activities [65]. If there is no added value for routine diag-
nosis, the cost of WGS will have to be covered by lim-
ited public health budgets.
As a limitation, the relatively low response rate in-
duced a potential volunteer bias as those public health
experts being more interested and/or experienced in
the field could be more likely to participate in the sur-
vey. Yet, 21% of the participants indicated that they
were ‘not at all’ familiar with sequencing technologies
and pathogen genomics. Further, we noticed a possible
underrepresentation of the food, animal and environ-
mental field in comparison to the human field, as well
as a low number of bioinformaticians in the survey. In
addition, public health professionals from the Belgian
Institute for Health (Sciensano) might be overrepre-
sented. The majority of microbiologists participating in
the survey are based in a NRC, emphasizing surveil-
lance activities and hence less weight to routine diag-
nostics. Given this potential imbalance, it is important
to take into account the distribution of profiles within
the study population while interpreting the results.
However, it is difficult to ascertain the true underlying
distribution of the different professional groups within
the target population. Another limitation of the study is
that the specific terminology used in the questions may
not have been uniformly understood or consistently
interpreted by stakeholders with different professional
backgrounds [39].
Conclusion
Public health professionals working in the field of infec-
tious diseases in Belgium were in general enthusiastic
about public health agencies implementing pathogen
genomics for the surveillance and control of infectious
diseases. However, introducing genomic methods into
public health practice is inevitably linked to the decrease
in cost, the introduction in routine activities of frontline
clinical labs, the identification of field applications in
public health, and the necessary development of new
competencies. The results of the survey confirm the
need to increase genomic literacy by offering dedicated
training opportunities among public health professionals,
especially for the data end-users including epidemiolo-
gists, clinicians, and infection control practitioners, en-
abling them to critically assess the utility and feasibility
of implementing pathogen genomics in their work activ-
ities. As such, those at the forefront (i.e. end-users) may
act as “honest brokers” responsible for evaluating the
added value of genomic application. In the end, the main
driver for the advancement of pathogen genomics in
public health practice depends on the added value of this
information for the different clinical and public health
needs. Further, inter-disciplinary (between epidemiolo-
gists, microbiologists and bioinformaticians) and inter-
sectoral (One Health context) collaboration should be
improved in the future to pool expertise and to ensure
an integrated and cohesive system for the management
of infectious diseases. In terms of feasibility, respondents
in this survey were mainly concerned, like their peers in
similar European surveys, about data integration, data
sharing, and the cost of sequencing technologies. Over-
all, this survey helps to better understand the perceived
utility and feasibility of pathogen genomics according to
public health professionals and can inform further guid-
ance to facilitate its implementation in Belgium. Future
challenges can be anticipated by performing a similar
survey among public health experts based in a country
that already progressed further in the process of imple-
menting pathogen genomics within their public health
surveillance system.
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